Applied DNA Sciences, Inc. (APDN)
Company Description
Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes.
The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims.
It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark.
In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies.
Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes.
The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002.
Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.

Country | United States |
Founded | 1983 |
Industry | Electronic Equipment, Instruments & Components |
Sector | Information Technology |
Employees | 78 |
CEO | James Hayward |
Contact Details
Address:
50 Health Sciences Dr Stony Brook, New York 11790-3349 United States | |
Phone | 631 840 8800 |
Website | adnas.com |
Stock Details
Ticker Symbol | APDN |
Exchange | NASDAQ |
Fiscal Year | October - September |
Reporting Currency | US Dollars |
CIK Code | 0000744452 |
CUSIP Number | 03815U102 |
ISIN Number | US03815U3005 |
Employer ID | 59-2262718 |
SIC Code | 2865 |
Key Executives
Name | Position |
---|---|
Dr. James A. Hayward Ph.D., Sc.D. | Chairman, President and Chief Executive Officer |
Beth M. Jantzen CPA, CPA | Chief Financial Officer |
Judith Murrah | Chief Operating Officer, Chief Information Officer and Secretary |
Scott L. Anchin | Strategic Advisor and Independent Director |
Sanjay M. Hurry | Executive Director of Investor Relations and Corporate Communications |
Clay Shorrock Esq., J.D. | Chief Legal Officer and Executive Director of Business Development |
John Shearman | Executive Director of Marketing and Cannabis Business |
Tony Benson | Managing Director of EMEA |
Janice Meraglia | Vice President, Gov. and Military Programs |
MeiLin Wan | Vice President of Textile Sales |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 12, 2022 | 8-K | Current report |
May 12, 2022 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
Feb 23, 2022 | 424B5 | Prospectus [Rule 424(b)(5)] |
Feb 22, 2022 | 8-K | Current report |
Feb 14, 2022 | SC 13D | General statement of acquisition of beneficial ownership |
Feb 14, 2022 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals |
Feb 10, 2022 | 8-K | Current report |
Feb 10, 2022 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
Jan 28, 2022 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] |
Jan 13, 2022 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals |